Treatment of acute Escherichia coli mastitis in cows with enrofloxacin: effect on clinical signs and chemiluminescence of circulating neutrophils.
We have studied the effect of treatment with enrofloxacin on local and general clinical signs and chemiluminescence of circulating polymorphonuclear leucocytes during experimentally induced Escherichia coli mastitis in cows immediately afer parturition. Twelve cows were infected with 10(4) cfu Esch. coli P4:032 into both left quarters. Six cows received an intravenous injection of 5 mg enrofloxacin/kg at 10 h after infection and a second enrofloxacin treatment administered subcutaneously at 30 h post infection. The other six cows were controls that received no treatment. General clinical signs (fever, tachycardia, loss of appetite, reduced rumen motility and depression) were similar in both groups. Local clinical signs, such as swelling, pain and firmness of the inflamed mammary quarters, were less severe in the treated cows. We saw no difference in the appearance of the milk: flecks and watery or purulent milk were observed in both groups. The beneficial effects of treatment with enrofloxacin were mainly on milk production and composition. The decline in milk production and the changes in milk concentrations of lactose, Na+ and bovine serum albumin were less pronounced in the treated cows. Treatment with enrofloxacin accelerated the clearance of bacteria from the infected quarters, but had no effect on the chemiluminescence response of isolated polymorphonuclear leucocytes. The changes in the number of circulating leucocytes and the appearance of immature neutrophils in the circulation of the treated cows indicated possible beneficial effects on migration of neutrophils into the inflamed glands. Higher milk somatic cell counts in the treated cows supported this hypothesis. The results of this study indicated that treating cows that have been experimentally infected with Esch. coli mastitis after parturition with enrofloxacin reduced the severity of the disease, especially the decline in milk production and the changes in milk composition.
Hoeben
B D
BD
Department of Physiology, Biochemistry and Biometrics, Milk Secretion and Mastitis Research Centre, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Monfardini
E
E
Burvenich
C
C
Hamann
J
J
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002417:Cattle / Q000502:physiology; D002452:Cell Count / Q000662:veterinary; D000077422:Enrofloxacin; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D005260:Female; D024841:Fluoroquinolones; D007774:Lactation / Q000187:drug effects*; D008163:Luminescent Measurements; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008892:Milk / Q000737:chemistry* / Q000166:cytology / Q000378:metabolism / Q000382:microbiology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin